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ABSTRACT We demonstrate the use of representational
difference analysis for cloning probes that detect DNA loss
and amplification in tumors. UsingDNA isolated from human
tumor cell lines to drive hybridization against matched nor-
mal DNA, we were able to identify six genomic regions that are
homozygously deleted in cultured cancer cells. When this
method was applied in the reverse way, using normal DNA to
drive hybridization against tumor cell DNA, we readily iso-
lated probes detecting amplification. Representational differ-
ence analysis was also performed on DNAs derived from
tumor biopsies, and we thereby discovered a probe detecting
very frequent homozygous loss in colon cancer cell lines and
located on chromosome 3p.
A variety of genetic lesions are found in tumors, including
rearrangement, gene amplification, point mutation, deletion,
and acquisition of viral genomes (1, 2). Delineating the genes
involved has often led to important new insights into the
pathophysiology of cancer. Therefore, efficient methods for
the discovery of new genetic lesions in tumors may accelerate
our management of that disease. Recently we described a
method, called representational difference analysis (RDA),
for analyzing the differences between complex but highly
related genomes (3).
RDA combines three elements: representation, subtractive
enrichment, and kinetic enrichment. The procedure is carried
out in two stages. The first comprises the preparation of
representations for driver and tester DNAs, during which small
restriction endonuclease fragments (called ARFs) are ligated
to oligonucleotide adapters and amplified by the polymerase
chain reaction (PCR). The second stage is comprised of the
reiterative hybridization/selection steps. Prior to the hybrid-
ization/selection step, only tester molecules are fitted with a
new pair of defined oligonucleotides at their 5' ends. After
reannealing tester and driver, the mixture of molecules is
treated with DNA polymerase. This adds the complement of
the defined oligonucleotides to both 3' ends of only self rean-
nealed tester DNA fragments. When the defined oligonucleotide
is used as primer in PCR of the mixture, such molecules can
participate in exponential amplification. This serves three pur-
poses. (i) Molecules of tester that reanneal to the excess of driver
are "subtracted out" since the heteroduplexes they form with
driver have the primer complement on one end only, thus leading
to inefficient, linear amplification of only one strand. (ii) Abun-
dant sequences of tester will reanneal faster than less abundant
ones (kinetic enrichment) so that sequences that are enriched or
amplified become even more enriched. (iii) PCR amplification
increases the yield so that the hybridization/selection step can be
reiterated or the product can be cloned and analyzed. Two of
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three rounds of hybridization/selection are employed to achieve
full purification of the difference products.
RDA may be used in two ways. (i) With tumor DNA taken
as driver, and matched normalDNA as tester, one may identify
the allelic loss of polymorphic loci and hemizygous or homozy-
gous deletions leading to the loss of restriction endonuclease
fragments in the tumor. (ii) With tumor DNA taken as tester,
and matched normal DNA as driver, one may detect small
restriction endonuclease fragments present only in the tumor
genome arising following viral infection, genetic rearrange-
ment, or point mutation (3). In the same manner, but by a
different mechanism, one can identify restriction endonucle-
ase fragments that have increased in copy number due to gene
amplification in the tumor. Using these two approaches we
have identified seven genomic loci that appear to be homozy-
gously lost in different tumor cell lines and two loci that have
undergone gene amplification. The probes marking these loci
may prove to be valuable tools in the search for recessive and
dominant oncogenes.
MATERIALS AND METHODS
Cell Lines and DNA Samples. Renal cell carcinoma (RCC)
cell lines UOK112, UOK114, UOK124, UOK132, UOK108,
UOK111, UOK127, UOK146, and UOK154 and normal DNAs
from the same patients were obtained as described (4). Colorectal
cancer cell lines VACO 429, VACO 441,VACO 432, VACO 456,
VACO 476, and RBX and matched normal DNAs were estab-
lished according to ref. 5. Cell line NCI H1770 (small cell lung
carcinoma) and Epstein-Barr virus (EBV)-immortalized lym-
phocytes from the same patient were supplied by J. D. Minna
(Southwestern Medical School, Dallas). DNAs from the mela-
noma tumor cell lines AH-Mel, FF-Mel, BD-Mel, and DX-Mel
and matched EBV-immortalized cells were the gift of A. Hough-
ton (Memorial Sloan-Kettering Cancer Center). Cell lines A382
(astrocytoma), VM-CUB-2 (bladder cancer), SK-LC-6, SK-LC-
13, SK-LC-14, SK-LC-17, and SHP-77 (lung cancers), and
WILTU-1 (Wilms tumor) were from the J. Fogh collection
(Memorial Sloan-Kettering Cancer Center). All other tumor cell
lines were obtained from the American Type Culture Collection.
DNAs NA04844 and NA11102 and human/rodent somatic cell
hybrid mapping panel no. 2 were purchased from the NIGMS
Human Genetic Mutant Cell Repository (Camden, NJ). The
"standard blotting panel" included Bgl II digests of DNAs from
tumor cell lines BD-Mel and AH-Mel (melanomas); T24 and
VM-CUB-2 (bladder cancers); SK-BR-3 and MCF7 (breast
cancers); HT-29, SW480, and SW620 (colon cancers); A-172 and
U-118 MG (glioblastomas); A-382 (astrocytoma); NCI H1770,
SK-LU-1, SK-LC-6, SK-LC-13, SK-LC-14, SK-LC-17, and
Abbreviations: RDA, representational difference analysis; RCC, renal
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SHP-77 (lung cancers); SK-N-MC, SK-N-SH, and IMR-5, (neu-
roblastomas); G-401 (Wilms tumor); and normal control DNA
NA04844. Allele frequency blots were prepared using Bgl II
digests of human DNAs from various races (allele frequency kit,
BIOS Laboratories, New Haven, CT). The standard PCR panel
included DNAs from tumor cell lines BT-20, MCF7, SK-BR-3,
T-47D, BT-549, MDA-MBA-435S, MDA-MB-436, MDA-MB-
231, MDA-MB-453, and MDA-MB-468 (breast cancers);
UOK124, UOK161, UOK114, UOK112, UOK132, UOK154,
UOK127, UOK111, UOK146, and UOK108 (RCCs); LS180,
SW403, SW480, HT-29, LoVo, DLD-1, Caco-2, HCT-15, VACO
429, and VACO 441 (colon cancers); FF-Mel, BD-Mel, AH-Mel,
DX-Mel, HT-144, SK-Mel-2, SK-Mel-3, G-361, WM266-4, and
Malme-3M (melanomas); T24, VM-CUB-2, UM-UC-3, J82,
SCaBER, HT-1376, RT-4, and HT-1197 (bladder cancers); and
normal control DNA NA04844. Tumor and normal cells were
grown as recommended and DNAs were purified using cell
culture DNA Maxi kit (Qiagen, Chatsworth, CA). Diploid and
aneuploid nuclei were separated by flow cytometry from a biopsy
of a patient with Barrett esophagus (6), and 100 ng ofDNA from
each diploid and aneuploid fraction (105 nuclei each) was purified
after lysis in SDS/proteinase K buffer, phenol/chloroform ex-
traction, and ethanol precipitation.
RDA. The RDA procedure was performed as described (3,
7) using Bgl II restriction endonuclease (New England Bio-
labs). A more complete protocol is available upon request (8).
When DNAs from flow-sorted material were used, 100 ng of
each driver and tester was digested with Bgl II and ligated to
adaptors in a volume 30 Al as described (3). After ligation, 10
,ug of tRNA (5 mg/ml), 90 ,ul of TE buffer, 30 ,ul of 10 M
ammoninum acetate, and 380 ,lI of ethanol were added. The
DNA pellet was recovered by centrifugation and dissolved in
10 Al of TE buffer. Forty microliters of the DNA ligate was
PCR amplified for 20 cycles in a volume of 400 ,lI as described
(3) taking two tubes for preparation of driver and two tubes for
preparation of tester representation. To get sufficient quantity
of DNA, 40 ,ul of the product of the first PCR was directly
added to each of 12 tubes used for preparation of driver
representation and reamplified for 5 cycles in a volume of 400
,ul under standard conditions (7). The subsequent PCR am-
plification of tester representation was made in the same way,
taking 2 tubes. All subsequent steps were performed as described
(3). RDA difference products were digested with Bgl II, ligated
to BamHI-digested and dephosphorylated pBluescript SK(-)
(Stratagene), and transformed into Escherichia coli XL-Blue
competent cells according to the supplier's recommendations.
Characterization and Mapping of RDA Probes. Plasmid
inserts were PCR amplified and those with distinct sizes were
selected, purified, and hybridized to Southern blots containing
Bgl II representations of driver, tester, one normal male, and
one normal female DNA prepared as described (7). Sequences
present in tester but not in driver representations were hy-
bridized to Southern blots containing Bgl II-digested DNAs
from the standard blotting panel and to allele frequency blots.
These blots were washed two times, 30 min each, in 0.1X
SSC/0.5% SDS at 68°C. Selected plasmid inserts were se-
quenced on both strands, using Sequenase T7 DNA poly-
merase reagent kit (United States Biochemical) as recom-
mended by the supplier. Oligonucleotides derived from the
sequences were synthesized and used for screening the stan-
dard PCR panel of DNAs. Two hundred fifty nanograms of
template was taken per each 100-pul PCR containing 1 ,uM
primers. Amplification was made for 32 cycles as described (7).
Negative reactions were independently repeated two times.
Mapping of probes on human chromosomes was performed
by PCR using 250 ng of DNAs from National Institute of
General Medical Sciences human/rodent somatic cell hybrid
mapping panel no. 2 as templates under the same conditions
(7). To sublocalize probes on chromosome 3, DNA from
hybrid clone GM 11102 retaining the der(3) t(3;16) (ql3.2;ql3)
chromosome was used (NIGMS Human Genetic Mutant Cell
Repository). Fluorescence in situ hybridization (FISH) was per-
formed as described (9).
RESULTS
Tumor DNA as Driver. We performed RDA on 16 individ-
ual pairs of tumor DNAs (used as driver) and matched normal
DNAs (used as tester) derived from the same patient, as
otherwise cloning of polymorphic differences between differ-
ent individuals predominates. In all cases, we used Bgl II as the
restriction endonuclease to prepare representations. Pure
tumor DNAs were isolated from 15 tumor cell lines (including
9 RCCs and 6 colon cancer cell lines), and normal DNA was
derived from unaffected blood or tissue but not from EBV-
immortalized cell lines lest viral DNA fragments be cloned. In
one case we used a fluorescence-activated cell sorter to fraction-
ate nuclei from an esophageal cancer biopsy into aneuploid and
diploid fractions that were used for preparation of driver and
tester DNA, respectively.
In each application of RDA, 2-13 difference products were
observed and cloned into plasmids. Plasmid clones were picked
at random and inserts of different sizes were analyzed by
hybridization to blots containing representations from the
normal (tester) and tumor (driver) DNAs, as well as Bgl II
Table 1. Analysis of RDA probes derived using tumor DNA
as driver
Cell line
RCC
UOK112 (d)
UOK114 (9)
UOK124 (9)
UOK132 (d)
UOK108 (9)
UOK111 (9)
UOK127 (d)
UOK146 (9)
UOK154 (9)
Colon cancer
VACO 429 (d)
VACO 441 (9)
VACO 432 (d)
VACO 456 (9)
VACO 576 (9)
RBX (d)
Barrett esophagus
BE 758 (FACS-
sorted nuclei) (d)
Total
Selected
for initial
characterization
Found to be
informative*
13t 13 (0/13/0)
12t 4 (3/0/1)
12t 4 (4/0/0)
lot 9 (3/6/0)
2 2 (2/0/0)
5 5 (5/0/0)
3 3 (2/1t/0)
3 3 (1/1t/1)
5 1 (1/0/0)
2 1 (0/0/1)
3 3 (1/0/2)
2 1 (1/0/0)
2 1 (1/0/0)
2 2 (2/0/0)
2 1 (1/0/0)
5 5 (0/4/1§)
83 58 (27/25/6)
FACS, fluorescence-activated cell sorter.
*Entries are a (b/c/d), where a is the total number of probes detecting
DNA loss in tumors, judged to be: b, LOH; c, hemizygous loss; d,
presumably homozygous loss (see Discussion). All but two probes
judged to detect hemizygous loss were derived from the Y chromo-
some. The difference between quantities of initially selected probes
(83) and informative probes (58) was due to the presence of the
repeat sequences (9 cases), non-human DNA contaminating tester (5
cases), and single copy sequences present in tester and driver DNAs
(11 cases).
tThe difference products after two rounds of hybridization/selection
were cloned; in all of the rest of the experiments cloning was
performed after three rounds.
*Probes 127-1 and 146-1 were found to be deletion polymorphisms,
absent on both autosomes of 7 of 35 and 3 of 35 normal humans,
respectively.
§This result is presumed but was not confirmed because of the small
amount of sorted tumor nuclei available.
Proc. Natt Acad Sci USA 92 (1995)
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Table 2. Homozygous losses detected in tumor cell lines
Chromo- Homo- PCR
some zygous product,
Probe location loss*t Sequences of primers used for PCR bp
UOK114-18 3p 1/74 CATTTCTTTAGGGTTCATTGTTGGAGC 293
GAGCCCAGCCAGCAGTCCCACC
UOK146-4 11 1/113 CCATGCTGCCTCCGTTGACACTCA 283
TGGCAACAATATCCATCCCTTTCCTG
UOK124-6t 2 2/113 GTCTTCTCTCCCTCTTTCCCTCCC 319
TGGCAGTAGAAGAGGAAAGATGTGTG
UOK146-8t 9 13/113 TGTGCTCCCAGTCCTGCAGTCATC 261
AGGGAACTCTGATGGTAGACTGGTC
UOK132-12t 9 6/86 GCCCCTCTAAAAGATAAGGTCTTGGT 272
GATCTGAGCCCCTGGAAGAAGTTAG
VACO 429-6 20 1/86 GGGAACAGTTCTCTTACAGCCACAC 351
ACAGAGGTGACAACAAGGTCAGTGG
VACO 441-1 18 1/86 CCAGCTGTGTCCTCTCAGCAACAG 268
ACATGATGCTGGCCTAGGTGAACTG
VACO 441-9 18 1/86 TCTAGGAACTGCCAGTGAGTGCTTG 244
GTACTAACCAAGGAGCTGGTGACAC
BE758-6 3p 6/86 GCTAAGCCTGGGGGAGTTGCTGAC 315
GATTACTAAGGCTTTGAAAGCTGGCC
*The numbers show the ratio of the number of cell lines with apparent homozygous loss (see Discussion) to the total number
of analyzed cell lines. The primary determination was by PCR. The losses were detected in the following cell lines: probe
UOK114-18 in UOK114;t probe UOK146-4 in UOK146; probe UOK124-6 in UOK141 and VM-CUB-2; probe UOK146-8
in UOK108, UOK122LN, UOK162, AH-Mel, Malme-3M, UM-UC-3, RT-4, MDA-MB-231, A-382, U-118 MG, A-172,
SK-LU-1, and SK-LC-14; probe 132-12 in AH-Mel,t FF-Mel,t MDA-MB-231, A-382, U-118 MG, and A-172; probe VACO
429-6 in VACO 429; probes VACO 441-1 and VACO 441-9 in VACO 441; probe BE758-6 in LS180,t SW480,t HT-29,t
LoVo,t MDA-MB-436,t and VM-CUB-2.t See text for origins of cell lines.
tPCR data were additionally confirmed by genomic Southern blotting for the indicated cell lines.
tThe probe was found to detect LOH in the initial normal/tumor DNA pair.
representations of normal male and female DNAs. The "in-
formative" probes, which were hybridizing to one band on a
blot, and were absent in the driver representation, were taken
for further analysis, except for those that derived from the Y
chromosome (loss of the Y chromosome information was
frequently observed in RCCs). In search for clones detecting
single copy sequences that are frequently lost in tumors,
informative probes were hybridized to blots containing Bgl
II-digested DNAs from a standard blotting panel of human
tumor cell lines. Those probes that were commonly polymor-
phic at Bgl II sites were presumed to have arisen by loss of
heterozygosity (LOH) and were not further studied unless they
did not detect any bands in at least one tumor DNA on a blot.
Probes of this type, as well as the remaining nonpolymorphic
single copy probes, were sequenced, and oligonucleotides
derived from the sequence were synthesized to be used for
PCR screening of total genomic DNA from tester, driver, and
panels of human tumor cell lines. When we could not detect
probe sequences in the genomic DNA that was used as driver,
we generally assumed that the probe detected homozygous
deletion. All probes absent in two or more DNA samples from
standard PCR panel were hybridized to allele frequency blots
containing Bgl II digests of human DNAs from various races.
This way we were able to find two probes that did not hybridize
to any sequences in several normal human DNAs. We thus
presume that these two probes actually detect hemizygous loss
of a deletion polymorphism (see Table 1, footnote t). Tables
1 and 2 summarize all of our results obtained using tumorDNA
as driver.
Typical results and analysis are shown in Fig. 1. In this
particular case, RDA was performed using DNA from the
RCC cell line UOK146 as driver. One of the probes
(UOK146-8) cloned from the third round of hybridization/
selection (Fig. 1A, lane c) was found to be absent in the Bgl II
representation of the tumor DNA. It was further analyzed by
Southern blotting and PCR (Fig. 1 B and C, respectively),
indicating its frequent homozygous loss in many tumor cell
lines. Subsequent PCR analysis of driver and tester DNAs
indicated that UOK146-8 in fact detected loss of a small allele
of a rare Bgl II polymorphism in the cell line UOK146 (data
not shown) and was present in the difference product due to
LOH rather than homozygous loss in the original tumor. Probe
UOK146-8 represents one of three probes detecting apparent
homozygous loss in at least one tumor source but isolated by
virtue of LOH in the original tumor (see Table 2).
All probes that detected homozygous loss in at least one
tumor cell line were mapped to human chromosomes using a
panel of monochromosomal human/rodent somatic cell hy-
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FIG. 1. Cloning of probes detecting DNA losses in RCC cell line
UOK146 (tumorDNA used as driver). (A) Agarose gel electrophoresis
of difference products obtained after the first (lane a), second (lane
b), and third (lane c) hybridization/selection steps. Sizes are indicated
in bp. (B) Autoradiogram obtained after hybridization of probe 146-8
(350 bp in length) to Southern blot containing Bgl II-digested DNAs
from indicated tumor cell lines. Sizes are indicated in kb. (C) Agarose
gel electrophoresis of PCR products amplified from indicated tumor
cell line DNAs using primers derived from the 146-8 sequence
(expected fragment length, 261 bp). Sizes are indicated in bp.
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brids (see Materials and Methods). In two cases, an additional
human/rodent hybrid was used to resolve location to 3p or 3q
(see Table 2).
Tumor DNA as Tester. We also used RDA by taking DNA
from tumor cell lines as tester and DNA from matched
normals as driver. The cell lines used were melanoma (AH-
Mel), small cell carcinoma of the lung (NCI H1770, gift of John
Minna), and two RCC cell lines (UOK161 and UOK124). In
two cases (AH-Mel and NCI H1770) difference products were
observed and were discernible even after the first round of
hybridization/selection. In each of these cases individual prod-
ucts cloned from the second round of hybridization/selection
detected high-level amplifications (30- to 100-fold) in the
tumor DNA used as tester. Additionally, RDA products from
NCI H1770 were found to be amplified in a neuroblastoma cell
line, IMR-5. The sequences from NCI H1770 were mapped to
chromosome 2, and those from AH-Mel were mapped to
chromosome 3. The entirety of the RDA product from the
second round of hybridization/selection of the melanoma
tumor cell line was used as a probe for FISH to metaphase
preparations from the AH-Mel cell line. Two and in some cases
three homogeneously staining regions were readily observed in
tumor cells with this probe (see Fig. 2).
The presence of amplified sequences from tumors in the
RDA product even after one round of hybridization/selection
suggested to us that such difference products would dominate
over single copy sequence differences and hence that the
detection of gene amplification might not require matched
tumor and normal DNAs. To test this idea, we took AH-Mel
DNA as tester and either a single or pooled DNA from 10
unrelated humans as driver. In either case, RDA products
were observed even after one round of hybridization/
selection, and difference products obtained after the second
round were found to map to the same amplified region in
AH-Mel as the RDA products found using the matched
normal DNA as driver.
DISCUSSION
The RDA methodology may be successfully applied to the
analysis of genetic lesions in tumors in two formats. In the first
FIG. 2. Homogeneously staining regions detected by FISH of
metaphase chromosomes from the AH-Mel cell line with nick-
translated total difference product obtained after two rounds of
hybridization/selection (tumor DNA used as tester).
format, the use of tumor DNA as driver and normal DNA as
tester leads to the discovery of probes that detect "loss" of
information in tumors: in the present cases, LOH, hemizygous
loss, and homozygous loss. Such losses may indicate the loss of
function of a "tumor suppressor" gene, or a set of such genes,
that in some way contributes to the evolution of the neoplastic
population in its host. When tumor DNA was used as driver,
58 of 83 RDA products were informative-that is, detected
loss of genetic information in the tumor source under analy-
sis-and all 16 RDA comparisons of tumor and normal pairs
yielded informative probes. In the second format, the use of
tumor DNA as tester and normal DNA as driver leads to the
discovery of probes that detect "gain" of information in
tumors: in the present cases, DNA amplification. Such ampli-
fication may result in the increased production of certain
proteins, encoded by dominant oncogenes, that contribute to
the growth advantage of the neoplastic population in its host.
Gene amplification was observed in two of four RDA com-
parisons of matched normal and tumor cell line DNAs.
LOH is detected by RDA at polymorphic loci where only
one allele contains a small amplifiable restriction endonucle-
ase fragment (ARF), present in the representation of the
normal DNA, but lost in the tumor DNA. We estimate that
after digestion with a restriction endonuclease such as Bgl II,
polymorphic ARFs (or PARFs) occur at a frequency of about
one per 1-3 megabases in the human genome. We did not
further study the probes that detected LOH in tumor/normal
pairs, except for 3 of a total of 27 probes of this type, which
detected homozygous loss in at least one other tumor source.
Hemizygous loss can occur in tumors from males if part or
all of theY chromosome is lost. We observed this type of lesion
frequently in RCC, as have others previously (10). Hemizygous
loss can also occur if individuals have inherited only one copy
of certain autosomal sequences and the remaining copy is lost
by any of the same mechanisms that underlie LOH at poly-
morphic markers. We believe that two instances of loss we
observed were of this type because the probes in question
detected "deletion polymorphisms" in the human popula-
tion-i.e., sequences that are not present in all humans (see
Table 1, footnote t).
Homozygous loss occurs when both alleles of an autosome
are lost in the tumor cell. In general, LOH should occur in
bigger blocks than homozygous loss. Thus probes that detect
homozygous loss are more likely to be closely linked to a tumor
suppressor gene. Happily, such probes are readily found by
RDA. In our experiments, the ratio of the number of probes
detecting apparent homozygous loss to the number detecting
LOH was 6:27. Since a 10-kbp homozygously deleted region
would have about a 50% chance of containing an ARF, while
a 1-megabase loss on one of two autosomes would generate, on
average, only a single PARF, we can estimate that in the
tumors we have sampled the ratio of genome length that has
been homozygously deleted to the length that has lost het-
erozygosity is 6 x 10 x 103 to 27 x 106, or about 1-4.5 x 102.
We must take these numbers with caution because we have not
proven that the six probes that detect complete loss in the
tumor genome truly arose by homozygous loss. Some of these
might represent hemizygous loss at undetected rare deletion
polymorphisms. In fact, we expect that some deletion poly-
morphisms, being recessive organismic lethals, would not be
found in the human population in the homozygous state but
could occur in tumors by LOH if they were not cell lethals.
Of the total nine probes that detect homozygous loss, probes
UOK132-12 and UOK146-8 probably detect the region on
chromosome 9 previously known to undergo frequent ho-
mozygous loss; and the two probes from VACO 441 both
derive from the vicinity of the DCC locus on chromosome 18
(unpublished data), a region previously known to undergo
LOH. One probe, derived from the Barrett esophagus biopsy
(BE758-6), that detects frequent homozygous loss in colon
Proc- Natt Acad Sci USA 92 (1995)
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cancer and other cell lines, does not yet appear to map to a
known tumor suppressor locus (unpublished data). This probe
maps to 3p, and intensive study of the surrounding genomic
region is necessary. The other probes detect homozygous
deletion in at most two cell lines and do not yet appear to
coincide with known loci.
When tumor DNA is used as tester, RDA has the potential
to detect several types of genetic alterations, including the
presence of viral genomes, genomic rearrangements, and a
very small proportion of point mutations. Such genetic changes
can give rise to restriction endonuclease fragments present in
tumor that are not present in the matched normal DNA. In the
four tumor cell lines investigated here, no probes for lesions of
these types were encountered. Rather, RDA yielded probes
that detected highly amplified single copy sequences. These
probes do not arise because of absolute differences between
normal and tumor DNA, but because their relative abundance
in tumor has led to their kinetic enrichment during the RDA
procedure. For the isolation of highly amplified sequences in
tumor DNA, any normal human DNA can be used as driver,
providing a means to clone such sequences from any tumor
cell. The two regions we found amplified map to chromosomes
2 (from small cell lung cancer) and 3 (from melanoma). The
region on chromosome 2 is also found amplified in a neuro-
blastoma cell line and hence may contain N-myc (11). Ampli-
fication on chromosome 3 has not been previously described.
For the application of RDA to cancer, the source of driver
must be relatively free of the unique tester source (5%). While
this is not a problem when normal DNA is used as driver, the
tumor source for driver preparation should not be derived
from unprocessed biopsies because of the presence of con-
taminating normal stromal elements. Established tumor cell
lines are a convenient source of pure DNA, but the tester DNA
must come from the normal host, and this source is often no
longer available. Moreover, established tumor cell lines may
have accumulated genetic alterations that were not present in
the original tumor. We have experimented successfully with
flow-sorted nuclei from biopsies. This method of separating
tumor DNA from normal DNA is based on differences in
ploidy, but other methods (e.g., short-term culture and/or
separation of tumor cells from normal cells by surface antigens
or other properties) might be employed.
RDA will not detect all differences between tumor and
normal DNAs. First, only differences in the respective repre-
sentations can be found. Since a representation is of lower
complexity than the genomic DNA from which it derives, not
all differences will be represented. Second, since RDA is a
PCR-based methodology and multiple cycles of PCR are used
(in excess of 80 cycles for the representation and three rounds
of hybridization/selection), only the most efficiently amplifi-
able differences are readily detected. This probably explains
the relatively narrow size range (250-350 bp) of the probes we
isolated that detect homozygous deletions. Thus cloning the
differences between two samples by RDA using a single
restriction endonuclease will hardly exhaust all of their abun-
dant differences.
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